Research study · Clinical and Translational Oncology · 2026
The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients
Verified on PubMed Clinical Evidence Analysis
A 2026 study in Clinical and Translational Oncology tested tetrahydrocannabinol in sleep. The results were mixed and the study cannot prove cause. This study suggests that higher doses of cannabidiol may offer modest sleep benefits for cancer patients, though the evidence does not establish a clear cause-and-effect relationship.
In plain language
Study overview
This study looked at adults with cancer who joined a state medical cannabis program in Minnesota. Their records tracked how well they slept over time, along with how much of two cannabis compounds they were taking.
Findings
The results were mixed and the study cannot prove cause. Patients who took higher amounts of one compound, CBD, tended to report somewhat better sleep than those who took smaller amounts, while the other main compound, THC, showed no clear link to sleep changes.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Background: Despite limited research, cancer patients are opting for compounds found in cannabis, like tetrahydrocannabinol (THC) and cannabidiol (CBD), to improve their sleep. The purpose of this study was to examine the therapeutic value of cannabis for sleep. Methods: Patient-reported symptom responses were obtained from 1962 cancer patients enrolled in the Minnesota Medical Cannabis Program (MMCP) from 2015 to 2023. Multivariable logistic and linear regression models were used to evaluate the associations between changes in reported sleep disturbance scores and the dose of THC, the dose of CBD, and the cannabinoid ratio (THC:CBD). Results: Compared to the highest quintile category of CBD dose, lower dose quintiles were 29-35% less likely to be associated with at least a 30% improvement in sleep disturbance scores. Sleep disturbance scores improved by 1.87 points on a 0-10 ordinal scale for cancer patients with CBD doses in the top quintile, and approximately 1.5 points for doses in lower quintiles. THC and THC:CBD doses were not consistently related to changes in sleep disturbance scores. Conclusion: Higher CBD doses may be associated with clinically meaningful improvements in sleep in cancer patients enrolled in a medical cannabis program.
The paper
Citation
Reddy AC, Hampton JM, Park SJ, Dickerson F, Chewning B, Schmitz N, et al. The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients. Clinical and Translational Oncology (2026). PubMed 41120744 · DOI
Limitations the authors noted
Retrospective observational design; no control group and no randomization, so causal inference is not possible. Cannabis transaction data used as proxy for actual use; no adherence data. Sleep measured by a single self-reported 24-hour item, without objective measures such as actigraphy or polysomnography. No data on cancer type, stage, concurrent treatments, or prior cannabis use. Selection bias from exclusion of patients without at least two visits after 30 days; sample predominantly White and non-Hispanic, from one state. Mean improvement of 1.63 points is below the commonly cited 2-4 point threshold for clinically meaningful change; the 1.87 point CBD top-quintile result approaches but does not clearly reach this threshold. Limited capacity to separate THC and CBD effects given correlated dosing.
In practice
Why this matters
This study suggests that higher doses of cannabidiol may offer modest sleep benefits for cancer patients, though the evidence does not establish a clear cause-and-effect relationship.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding CBD and Cancer?
The results were mixed and the study cannot prove cause. Patients who took higher amounts of one compound, CBD, tended to report somewhat better sleep than those who took smaller amounts, while the other main compound, THC, showed no clear link to sleep changes.
What study limitations or clinical safeguards should patients keep in mind?
Retrospective observational design; no control group and no randomization, so causal inference is not possible. Cannabis transaction data used as proxy for actual use; no adherence data. Sleep measured by a single self-reported 24-hour item, without objective measures such as actigraphy or...
Browse related research
Condition: Cancer Condition: Sleep Condition: Sleep wake disorders Topic: CBD Topic: Medical cannabis Topic: THC
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on November 1, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.